Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Evaluation of the Pharmacokinetic Interaction Between Doravirine and Methadone.

Khalilieh S, Yee KL, Sanchez RI, Vaynshteyn K, Fan L, Searle S, Bouhajib M, Iwamoto M.

Clin Pharmacol Drug Dev. 2019 May 23. doi: 10.1002/cpdd.699. [Epub ahead of print]

PMID:
31120195
2.

Evaluation of the Pharmacokinetics of Metformin Following Coadministration With Doravirine in Healthy Volunteers.

Sanchez RI, Yee KL, Fan L, Cislak D, Martell M, Jordan HR, Iwamoto M, Khalilieh S.

Clin Pharmacol Drug Dev. 2019 Apr 11. doi: 10.1002/cpdd.685. [Epub ahead of print]

PMID:
30973682
3.

A Study to Evaluate Doravirine Pharmacokinetics When Coadministered With Acid-Reducing Agents.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Vaynshteyn K, Deschamps K, Martell M, Jordan HR, Iwamoto M.

J Clin Pharmacol. 2019 Aug;59(8):1093-1098. doi: 10.1002/jcph.1399. Epub 2019 Feb 28.

PMID:
30817001
4.

Doravirine and the Potential for CYP3A-Mediated Drug-Drug Interactions.

Khalilieh SG, Yee KL, Sanchez RI, Fan L, Anderson MS, Sura M, Laethem T, Rasmussen S, van Bortel L, van Lancker G, Iwamoto M.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02016-18. doi: 10.1128/AAC.02016-18. Print 2019 May.

5.

Investigation of Pharmacokinetic Interactions between Doravirine and Elbasvir-Grazoprevir and Ledipasvir-Sofosbuvir.

Ankrom W, Sanchez RI, Yee KL, Fan L, Mitra P, Wolford D, Triantafyllou I, Sterling LM, Stoch SA, Iwamoto M, Khalilieh S.

Antimicrob Agents Chemother. 2019 Apr 25;63(5). pii: e02491-18. doi: 10.1128/AAC.02491-18. Print 2019 May.

6.

Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.

Khalilieh S, Hussain A, Montgomery D, Levine V, Shaw PM, Bodrug I, Mekokishvili L, Bailey-Smith C, Glasgow XS, Cheng A, Martinho M, Iwamoto M.

Br J Clin Pharmacol. 2018 Oct;84(10):2292-2302. doi: 10.1111/bcp.13670. Epub 2018 Jul 31.

7.

Severe Renal Impairment Has Minimal Impact on Doravirine Pharmacokinetics.

Ankrom W, Yee KL, Sanchez RI, Adedoyin A, Fan L, Marbury T, Preston RA, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2018 Jul 27;62(8). pii: e00326-18. doi: 10.1128/AAC.00326-18. Print 2018 Aug.

8.

Multiple Doses of Rifabutin Reduce Exposure of Doravirine in Healthy Subjects.

Khalilieh SG, Yee KL, Sanchez RI, Liu R, Fan L, Martell M, Jordan H, Iwamoto M.

J Clin Pharmacol. 2018 May 3. doi: 10.1002/jcph.1103. [Epub ahead of print]

PMID:
29723418
9.

Characterisation of the absorption, distribution, metabolism, excretion and mass balance of doravirine, a non-nucleoside reverse transcriptase inhibitor in humans.

Sanchez RI, Fillgrove KL, Yee KL, Liang Y, Lu B, Tatavarti A, Liu R, Anderson MS, Behm MO, Fan L, Li Y, Butterton JR, Iwamoto M, Khalilieh SG.

Xenobiotica. 2019 Apr;49(4):422-432. doi: 10.1080/00498254.2018.1451667. Epub 2018 Mar 28.

PMID:
29557716
10.

Pharmacokinetics of Tildrakizumab (MK-3222), an Anti-IL-23 Monoclonal Antibody, After Intravenous or Subcutaneous Administration in Healthy Subjects.

Khalilieh S, Hodsman P, Xu C, Tzontcheva A, Glasgow S, Montgomery D.

Basic Clin Pharmacol Toxicol. 2018 Sep;123(3):294-300. doi: 10.1111/bcpt.13001. Epub 2018 Apr 20.

11.

A Randomized Trial to Assess the Effect of Doravirine on the QTc Interval Using a Single Supratherapeutic Dose in Healthy Adult Volunteers.

Khalilieh SG, Yee KL, Fan L, Liu R, Heber W, Dunzo E, Triantafyllou I, Hussaini A, Iwamoto M.

Clin Drug Investig. 2017 Oct;37(10):975-984. doi: 10.1007/s40261-017-0552-x.

PMID:
28785879
12.

The Effect of Single and Multiple Doses of Rifampin on the Pharmacokinetics of Doravirine in Healthy Subjects.

Yee KL, Khalilieh SG, Sanchez RI, Liu R, Anderson MS, Manthos H, Judge T, Brejda J, Butterton JR.

Clin Drug Investig. 2017 Jul;37(7):659-667. doi: 10.1007/s40261-017-0513-4.

PMID:
28353169
13.

Erratum to: A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):679-681. doi: 10.1007/s40262-017-0517-5. No abstract available.

PMID:
28185217
14.

Moderate Hepatic Impairment Does Not Affect Doravirine Pharmacokinetics.

Khalilieh S, Yee KL, Liu R, Fan L, Sanchez RI, Auger P, Triantafyllou I, Stypinski D, Lasseter KC, Marbury T, Iwamoto M.

J Clin Pharmacol. 2017 Jun;57(6):777-783. doi: 10.1002/jcph.857. Epub 2016 Dec 27.

PMID:
28026013
15.

Results of a Doravirine-Atorvastatin Drug-Drug Interaction Study.

Khalilieh S, Yee KL, Sanchez RI, Triantafyllou I, Fan L, Maklad N, Jordan H, Martell M, Iwamoto M.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01364-16. doi: 10.1128/AAC.01364-16. Print 2017 Feb.

16.

Evaluation of Doravirine Pharmacokinetics When Switching from Efavirenz to Doravirine in Healthy Subjects.

Yee KL, Sanchez RI, Auger P, Liu R, Fan L, Triantafyllou I, Lai MT, Di Spirito M, Iwamoto M, Khalilieh SG.

Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01757-16. doi: 10.1128/AAC.01757-16. Print 2017 Feb.

17.

A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir.

Anderson MS, Khalilieh S, Yee KL, Liu R, Fan L, Rizk ML, Shah V, Hussaini A, Song I, Ross LL, Butterton JR.

Clin Pharmacokinet. 2017 Jun;56(6):661-669. doi: 10.1007/s40262-016-0458-4. Erratum in: Clin Pharmacokinet. 2017 Jun;56(6):679-681.

PMID:
27699622
18.

Clinical pharmacology profile of boceprevir, a hepatitis C virus NS3 protease inhibitor: focus on drug-drug interactions.

Khalilieh S, Feng HP, Hulskotte EG, Wenning LA, Butterton JR.

Clin Pharmacokinet. 2015 Jun;54(6):599-614. doi: 10.1007/s40262-015-0260-8. Review.

PMID:
25787025
19.

Clinical improvement in psoriasis with specific targeting of interleukin-23.

Kopp T, Riedl E, Bangert C, Bowman EP, Greisenegger E, Horowitz A, Kittler H, Blumenschein WM, McClanahan TK, Marbury T, Zachariae C, Xu D, Hou XS, Mehta A, Zandvliet AS, Montgomery D, van Aarle F, Khalilieh S.

Nature. 2015 May 14;521(7551):222-6. doi: 10.1038/nature14175. Epub 2015 Mar 9.

PMID:
25754330
20.

The effects of the CXCR2 antagonist, MK-7123, on bone marrow functions in healthy subjects.

Hastrup N, Khalilieh S, Dale DC, Hanson LG, Magnusson P, Tzontcheva A, Tseng J, Huyck S, Rosenberg E, Krogsgaard K.

Cytokine. 2015 Apr;72(2):197-203. doi: 10.1016/j.cyto.2015.01.002. Epub 2015 Feb 4.

PMID:
25661195
21.

Tildrakizumab, a novel anti-IL-23 monoclonal antibody, is unaffected by ethnic variability in Caucasian, Chinese, and Japanese subjects.

Zandvliet A, Glasgow S, Horowitz A, Montgomery D, Marjason J, Mehta A, Xu C, van Vugt M, Khalilieh S.

Int J Clin Pharmacol Ther. 2015 Feb;53(2):139-46. doi: 10.5414/CP202176.

PMID:
25546162
22.

Humoral immunity and delayed-type hypersensitivity in healthy subjects treated for 30 days with MK-7123, a selective CXCR2 antagonist.

Seiberling M, Kamtchoua T, Stryszak P, Ma X, Langdon RB, Khalilieh S.

Int Immunopharmacol. 2013 Oct;17(2):178-83. doi: 10.1016/j.intimp.2013.05.029. Epub 2013 Jun 19.

PMID:
23791619
23.

Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.

Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, Cheng K, Chin J, Colletti SL, Cote J, Khalilieh S, Liu J, Luo WL, Maclean AA, Peterson LB, Polis AB, Sirah W, Wu TJ, Liu X, Jin L, Wu K, Boatman PD, Semple G, Behan DP, Connolly DT, Lai E, Wagner JA, Wright SD, Cuffie C, Mitchel YB, Rader DJ, Paolini JF, Waters MG, Plump A.

Sci Transl Med. 2012 Aug 22;4(148):148ra115. doi: 10.1126/scitranslmed.3003877.

24.

SCH527123, a novel CXCR2 antagonist, inhibits ozone-induced neutrophilia in healthy subjects.

Holz O, Khalilieh S, Ludwig-Sengpiel A, Watz H, Stryszak P, Soni P, Tsai M, Sadeh J, Magnussen H.

Eur Respir J. 2010 Mar;35(3):564-70. doi: 10.1183/09031936.00048509. Epub 2009 Jul 30.

25.

Pharmacokinetics of desloratadine in children between 2 and 11 years of age.

Gupta S, Khalilieh S, Kantesaria B, Banfield C.

Br J Clin Pharmacol. 2007 May;63(5):534-40.

26.

Adult and paediatric poor metabolisers of desloratadine: an assessment of pharmacokinetics and safety.

Prenner B, Kim K, Gupta S, Khalilieh S, Kantesaria B, Manitpisitkul P, Lorber R, Wang Z, Lutsky B.

Expert Opin Drug Saf. 2006 Mar;5(2):211-23. Review.

PMID:
16503743
27.

Tegaserod coadministration does not alter the pharmacokinetics of theophylline in healthy subjects.

Zhou H, Khalilieh S, Svendsen K, Pommier F, Osborne S, Appel-Dingemanse S, Lasseter K, McLeod JF.

J Clin Pharmacol. 2001 Sep;41(9):987-93.

PMID:
11549104
28.

Effect of meal timing not critical for the pharmacokinetics of tegaserod (HTF 919).

Zhou H, Khalilieh S, Lau H, Guerret M, Osborne S, Alladina L, Laurent AL, McLeod JF.

J Clin Pharmacol. 1999 Sep;39(9):911-9.

PMID:
10471981

Supplemental Content

Loading ...
Support Center